
Brenda Libby Coleman
Examiner (ID: 13884, Phone: (571)272-0665 , Office: P/1624 )
| Most Active Art Unit | 1624 |
| Art Unit(s) | 1202, 2611, 1624, 1611 |
| Total Applications | 3154 |
| Issued Applications | 1967 |
| Pending Applications | 488 |
| Abandoned Applications | 741 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17141611
[patent_doc_number] => 20210309623
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-07
[patent_title] => CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE
[patent_app_type] => utility
[patent_app_number] => 17/197732
[patent_app_country] => US
[patent_app_date] => 2021-03-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20131
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -35
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17197732
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/197732 | Charged ion channel blockers and methods for use | Mar 9, 2021 | Issued |
Array
(
[id] => 16932317
[patent_doc_number] => 20210198206
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-01
[patent_title] => THERAPEUTIC COMPOUNDS AND COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 17/195243
[patent_app_country] => US
[patent_app_date] => 2021-03-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 60362
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17195243
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/195243 | Therapeutic compounds and compositions | Mar 7, 2021 | Issued |
Array
(
[id] => 19034036
[patent_doc_number] => 20240083851
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-14
[patent_title] => NOVEL OXIDIZED LAPPACONITINE DERIVATIVE AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/905798
[patent_app_country] => US
[patent_app_date] => 2021-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5640
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17905798
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/905798 | NOVEL OXIDIZED LAPPACONITINE DERIVATIVE AND USE THEREOF | Mar 4, 2021 | Pending |
Array
(
[id] => 18334439
[patent_doc_number] => 20230126387
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-27
[patent_title] => L-ERGOTHIONEINE-CONTAINING COMPOSITION
[patent_app_type] => utility
[patent_app_number] => 17/905626
[patent_app_country] => US
[patent_app_date] => 2021-03-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6808
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17905626
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/905626 | L-ergothioneine-containing composition | Mar 3, 2021 | Issued |
Array
(
[id] => 16991776
[patent_doc_number] => 20210230196
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-29
[patent_title] => Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes)
[patent_app_type] => utility
[patent_app_number] => 17/190924
[patent_app_country] => US
[patent_app_date] => 2021-03-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20457
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17190924
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/190924 | Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes) | Mar 2, 2021 | Abandoned |
Array
(
[id] => 18389885
[patent_doc_number] => 20230158103
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-25
[patent_title] => PLD FOR USE IN COMBINATION IN THE TREATMENT OF CORONAVIRUS
[patent_app_type] => utility
[patent_app_number] => 17/908531
[patent_app_country] => US
[patent_app_date] => 2021-03-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15638
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17908531
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/908531 | PLD FOR USE IN COMBINATION IN THE TREATMENT OF CORONAVIRUS | Mar 1, 2021 | Pending |
Array
(
[id] => 17982541
[patent_doc_number] => 20220348577
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-03
[patent_title] => CXCR4 Receptor Antagonists
[patent_app_type] => utility
[patent_app_number] => 17/190266
[patent_app_country] => US
[patent_app_date] => 2021-03-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34415
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17190266
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/190266 | CXCR4 Receptor Antagonists | Mar 1, 2021 | Abandoned |
Array
(
[id] => 20201513
[patent_doc_number] => 12404282
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-02
[patent_title] => Process for the purification of indole carbazole alkaloids
[patent_app_type] => utility
[patent_app_number] => 17/905327
[patent_app_country] => US
[patent_app_date] => 2021-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 1086
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17905327
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/905327 | Process for the purification of indole carbazole alkaloids | Feb 28, 2021 | Issued |
Array
(
[id] => 17214432
[patent_doc_number] => 20210347769
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-11
[patent_title] => METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND
[patent_app_type] => utility
[patent_app_number] => 17/180127
[patent_app_country] => US
[patent_app_date] => 2021-02-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49723
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17180127
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/180127 | Method for producing optically active compound | Feb 18, 2021 | Issued |
Array
(
[id] => 19060144
[patent_doc_number] => 11939352
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-26
[patent_title] => Potent aromatase inhibitors through fungal transformation of anti-cancer drug testolactone: an approach towards treatment of breast cancer
[patent_app_type] => utility
[patent_app_number] => 17/177209
[patent_app_country] => US
[patent_app_date] => 2021-02-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 2545
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17177209
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/177209 | Potent aromatase inhibitors through fungal transformation of anti-cancer drug testolactone: an approach towards treatment of breast cancer | Feb 16, 2021 | Issued |
Array
(
[id] => 18298850
[patent_doc_number] => 20230108536
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-06
[patent_title] => METHODS OF PREPARING CHIRAL BENZODIAZEPINONE DERIVATIVES
[patent_app_type] => utility
[patent_app_number] => 17/799680
[patent_app_country] => US
[patent_app_date] => 2021-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7253
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17799680
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/799680 | METHODS OF PREPARING CHIRAL BENZODIAZEPINONE DERIVATIVES | Feb 15, 2021 | Pending |
Array
(
[id] => 17256714
[patent_doc_number] => 20210369699
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-02
[patent_title] => TREATMENT OF LUPUS ERYTHEMATOSUS USING S-HYDROXYCHLOROQUINE
[patent_app_type] => utility
[patent_app_number] => 17/176679
[patent_app_country] => US
[patent_app_date] => 2021-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3538
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17176679
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/176679 | TREATMENT OF LUPUS ERYTHEMATOSUS USING S-HYDROXYCHLOROQUINE | Feb 15, 2021 | Abandoned |
Array
(
[id] => 17006991
[patent_doc_number] => 20210238152
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-05
[patent_title] => CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/170641
[patent_app_country] => US
[patent_app_date] => 2021-02-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26359
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17170641
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/170641 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | Feb 7, 2021 | Issued |
Array
(
[id] => 18869856
[patent_doc_number] => 11857636
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-02
[patent_title] => Bio-orthogonal drug activation
[patent_app_type] => utility
[patent_app_number] => 17/169217
[patent_app_country] => US
[patent_app_date] => 2021-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 9
[patent_no_of_words] => 26182
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 90
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17169217
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/169217 | Bio-orthogonal drug activation | Feb 4, 2021 | Issued |
Array
(
[id] => 18405736
[patent_doc_number] => 20230167087
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-01
[patent_title] => 2-[2-METHYLAZETIDIN-1-YL]-4-PHENYL-6-(TRIFLUOROMETHYL)-PYRIMIDINE COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 17/799026
[patent_app_country] => US
[patent_app_date] => 2021-02-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6022
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17799026
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/799026 | 2-[2-methylazetidin-1-yl]-4-phenyl-6-(trifluoromethyl)-pyrimidine compounds | Feb 4, 2021 | Issued |
Array
(
[id] => 16870023
[patent_doc_number] => 20210163490
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM
[patent_app_type] => utility
[patent_app_number] => 17/167865
[patent_app_country] => US
[patent_app_date] => 2021-02-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13683
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17167865
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/167865 | PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM | Feb 3, 2021 | Pending |
Array
(
[id] => 18056306
[patent_doc_number] => 20220387392
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-08
[patent_title] => METHODS AND COMPOSITIONS RELATED TO THE USE OF ERGOTHIONEINE
[patent_app_type] => utility
[patent_app_number] => 17/760056
[patent_app_country] => US
[patent_app_date] => 2021-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15406
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17760056
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/760056 | METHODS AND COMPOSITIONS RELATED TO THE USE OF ERGOTHIONEINE | Feb 2, 2021 | Abandoned |
Array
(
[id] => 16839381
[patent_doc_number] => 20210147393
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-20
[patent_title] => DIFLUOROMETHYL-PHENYL TRIAZOLES
[patent_app_type] => utility
[patent_app_number] => 17/160285
[patent_app_country] => US
[patent_app_date] => 2021-01-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11544
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 10
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17160285
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/160285 | DIFLUOROMETHYL-PHENYL TRIAZOLES | Jan 26, 2021 | Abandoned |
Array
(
[id] => 16839360
[patent_doc_number] => 20210147372
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-20
[patent_title] => BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS
[patent_app_type] => utility
[patent_app_number] => 17/153409
[patent_app_country] => US
[patent_app_date] => 2021-01-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57482
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17153409
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/153409 | Benzothiazepine compounds and their use as bile acid modulators | Jan 19, 2021 | Issued |
Array
(
[id] => 18177409
[patent_doc_number] => 20230038138
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => COMBINATION THERAPY FOR TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 17/758515
[patent_app_country] => US
[patent_app_date] => 2021-01-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5134
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17758515
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/758515 | COMBINATION THERAPY FOR TREATING CANCER | Jan 7, 2021 | Abandoned |